Brief: Oculis Holding Initiated Second Phase 3 Optimize-2 Trial With Ocs-01 Once Daily Eye Drop In Late 2023 & Topline Readout Expected Before End Of 2024
08/04/2024 12:34
April 8 (Reuters) - Oculis Holding AG CR5.F :
* POSITIVE RESULTS FROM PHASE 3 OPTIMIZE-1 TRIAL OF ONCE
DAILY
OCS-01 FOR THE TREATMENT OF INFLAMMATION AND PAIN FOLLOWING
CATARACT SURGERY PRESENTED AT THE 2024 AMERICAN SOCIETY OF
CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
* OCULIS HOLDING: INITIATED SECOND PHASE 3 OPTIMIZE-2 TRIAL
WITH
OCS-01 ONCE DAILY EYE DROP IN LATE 2023 & TOPLINE READOUT
EXPECTED BEFORE END OF 2024
Source text for Eikon: ID:nGNX7DFQDk
Further company coverage: CR5.F
((Reuters.Briefs@thomsonreuters.com;))